Two Phase 3 studies of the efficacy and safety of AR-13324 Ophthalmic Solution 0.02%: in Patients with Open Angle Glaucoma and Ocular Hypertension

Abstract Number: 4279

Author Block: L Jay Katz¹, Mark J. Weiss², Theresa Heah³, Casey Kopczynski⁴, Gary D. Novack⁵,⁶

¹ Glaucoma, Wills Eye, Philadelphia, Pennsylvania, United States; ² The Eye Institute, Tulsa, Oklahoma, United States; ³ Aerie Pharmaceuticals, Bedminster, California, United States; ⁴ Aerie Pharmaceuticals, Research Triangle Park, North Carolina, United States; ⁵ PharmaLogic Development, Inc., San Rafael, California, United States; ⁶ Pharmacology & Ophthalmology, University of California, Davis, California, United States

Disclosure Block: L Jay Katz, Aerie Pharmaceuticals (Code I (Personal Financial Interest)), Aerpio (Code C (Consultant)), Alimera (Code C (Consultant)), Allergan (Code C (Consultant)), Bausch + Lomb (Code C (Consultant)), Diopsys (Code C (Consultant)), Forsight Vision V (Code C (Consultant)), Glaukos (Code I (Personal Financial Interest)), Heidelberg (Code F (Financial Support)), Innfocus (Code C (Consultant)), Innfocus (Code C (Consultant)), Inotek (Code C (Consultant)), Mati (Code I (Personal Financial Interest)), Ocular therapeutix (Code C (Consultant)), Sensimed (Code C (Consultant)); Mark J. Weiss, Aerie Pharmaceuticals (Code F (Financial Support)), Theresa Heah, Aerie Pharmaceuticals (Code E (Employment)), Casey Kopczynski, Aerie Pharmaceuticals (Code E (Employment)), Gary D. Novack, Aerie Pharmaceuticals (Code C (Consultant)), Envisia (Code C (Consultant)), ForSight Vision5 (Code C (Consultant)), Peregrine (Code C (Consultant)), Polyactiva (Code C (Consultant)), Teva (Code C (Consultant))

Purpose: We compared the ocular hypotensive efficacy and safety of AR-13324 Ophthalmic Solution 0.02% to timolol ophthalmic solution 0.5% BID in patients with elevated intraocular pressure (IOP) (open angle glaucoma and ocular hypertension) in two Phase 3 studies Rocket 1 and Rocket 2 (R1, R2). AR-13324 inhibits both Rho kinase and the norepinephrine transporter and increases trabecular outflow, reduces aqueous humor formation, and decreases episcleral venous pressure in preclinical models.

Methods: Subjects with baseline IOP >20 and <27 mmHg (in R1), and >20 and <25 mmHg (in R2), were included in the primary efficacy analysis. In R1, patients were randomized to receive either AR-13324 0.2% QD (PM) or timolol 0.5% BID for 3 months, R2 was a 12 month study where AR-13324 0.2% was dosed QD and BID. In both studies, the efficacy endpoint was mean IOP at 8:00, 10:00, and 16:00 hours at Weeks 2, 6, and Month 3.

Results: A total of 411 subjects in R1 and 756 subjects in R2 were randomized. While AR-13324 0.2% QD did not meet the criteria for non-inferiority to timolol 0.5% BID in patients with baseline IOP <27 mmHg in R1, it was non-inferior to timolol 0.5% BID in a pre-specified analysis of subjects with baseline IOPs of ≤23 mmHg and in a post hoc analysis of subjects with baseline IOP <25 mmHg. In Rocket 2, both regimens of AR-13324 0.2% were non-inferior to timolol 0.5% BID in the primary population (baseline IOP < 25 mmHg). The most common safety finding was conjunctival hyperemia, which was of mild severity in a majority of subjects. The BID dosing regimen of AR-
13324 resulted in more ocular adverse events and treatment discontinuations than QD dosing.

**Conclusions:** AR-13324 0.2%, dosed QD and BID, was non-inferior to timolol 0.5% BID in subjects with baseline pressures below 25 mmHg, with a better safety and tolerability profile with QD dosing.

Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details. In these two large controlled studies, AR-13324, a new topical ocular solution working through several mechanisms, lowered intraocular pressure in patients with glaucoma and ocular hypertension, with relatively few safety issues.